N-[6-dodecoxy-5-[(6-dodecoxy-6-oxohexyl)azaniumyl]-6-oxohexyl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[6-dodecoxy-5-[(6-dodecoxy-6-oxohexyl)azaniumyl]-6-oxohexyl]carbamate
• 化学式: C37H72N2O6
• 分子量: 641.0
• InChiKey: LSDQUDYGWFSNGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  45
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Transdermal Pharmaceutical Compositions Including Testosterone and a C-SERM
  申请人：Professional Compounding Centers of America (PCCA)

  公开号：US20160051498A1

  公开（公告）日：2016-02-25

  Formulations for transdermal pharmaceutical compositions including a synergistic combination of low doses of testosterone with a selective estrogen receptor modulator (C-SERM) that are combined with transdermal permeation enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Transdermal pharmaceutical compositions include liquid dosage forms, such as, for example solutions, liquid sprays, lotions, and the like. Additionally, transdermal pharmaceutical compositions include semi-solid dosage forms, such as, for example emulsions, creams, gels, pastes, ointments, and the like. Transdermal pharmaceutical compositions will deliver testosterone and C-SERM through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of testosterone and C-SERM. The dosage regimen of the transdermal pharmaceutical compositions can be easily tailored for individual patients according to the baseline blood levels of testosterone and estradiol.
• Transdermal Pharmaceutical Compositions Including C-SERMs for Low Testosterone Levels in Men
  申请人：Professional Compounding Centers of America (PCCA)

  公开号：US20160051497A1

  公开（公告）日：2016-02-25

  Formulations for transdermal pharmaceutical compositions including clomiphene-like selective estrogen receptor modulators (C-SERMs) in combination with transdermal penetration enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and are administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency in male hypogonadism or male infertility. Transdermal pharmaceutical compositions include a range of dosage forms, such as, for example solutions, liquid sprays, lotions, emulsions, creams, pastes, and ointments, among other dosage forms that exhibit transdermal properties, and provide transdermal delivery of C-SERMs. Transdermal pharmaceutical compositions will deliver C-SERMs through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of C-SERMs. The dosage regimen of the transdermal pharmaceutical compositions can be easily tailored for individual patients according to the baseline blood levels of testosterone and estradiol.
• Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
  申请人：Professional Compounding Centers of America (PCCA)

  公开号：US20160051565A1

  公开（公告）日：2016-02-25

  Formulations for transdermal pharmaceutical compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transdermal permeation enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Transdermal pharmaceutical compositions include liquid dosage forms, such as, for example solutions, liquid sprays, lotions, and the like. Additionally, transdermal pharmaceutical compositions include semi-solid dosage forms, such as, for example emulsions, creams, gels, pastes, ointments, and the like. Transdermal pharmaceutical compositions will deliver testosterone and AI through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of testosterone and AI. The dosage regimen of the transdermal pharmaceutical compositions can be easily tailored for individual patients according to the baseline blood levels of testosterone and estradiol.
• Vasodilator Formulation and Method of Use
  申请人：ATP INSTITUTE PTY LTD

  公开号：US20160256509A1

  公开（公告）日：2016-09-08

  A topically admimstrable vasodilator formulation comprises arginine and/or one or more derivatives thereof, black pepper extract and/or one or more components or derivatives thereof; and peppermint extract and/or one or more components or derivatives thereof. The formulation may further comprise rosemary oil, a penetration enhancers, an ecdysteroid and/or one or more other agents that enhance the vasodilator activity of the formulation. The valodilator formulation may be suitable for treating or preventing a disease, disorder or condition associated with a decrease and/or impairment of blood flow in a subject by topically administration to the subject.
• Pain Relief Formulation and Method of Treatment
  申请人：ATP Institute Pty Ltd

  公开号：US20200046790A1

  公开（公告）日：2020-02-13

  A topically administrable pain relief formulation comprises a Kunzea ambigua extract or one or more components or derivatives thereof; Menthol; Capsaicin; and a Hypericum perforatum extract or one or more components or derivatives thereof. The formulation may further comprise methyl salicylate, black pepper and/or an anti-inflammatory agent. The formulation may be used to treat or prevent pain such as arthritis neck pain, shoulder pain, back pain, preoperative and/or postoperative pain and pain associated with minor or traumatic injuries or other diseases or conditions.